Document:

Exhibit 4.1

 

THE REGISTERED HOLDER OF THIS PURCHASE WARRANT
BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED
HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD
OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE COMMENCEMENT OF SALES OF THE OFFERING TO ANYONE OTHER THAN (I) UNIVEST SECURITIES, LLC,
OR A REPRESENTATIVE OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF UNIVEST SECURITIES,
LLC, OR OF ANY SUCH UNDERWRITERS OR SELECTED DEALER.

 

THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR
TO [●], 202[●]. VOID AFTER 5:00 P.M., EASTERN TIME, [●], 202[●].1

 

UNDERWRITERS’ WARRANT

 

FOR THE PURCHASE OF [●] ORDINARY SHARES

 

OF

 

LI BANG INTERNATIONAL CORPORATION INC.

 

1. Purchase Warrant. THIS CERTIFIES
THAT, pursuant to that certain Underwriting Agreement by and between Li Bang International Corporation Inc., a Cayman Islands exempted
company (the “Company”), on the one hand, and Univest Securities, LLC, on the other hand, dated [●], 202[●],
as amended (the “Underwriting Agreement”), [●] (“Holder”) and its assignees, as registered holders
of this Purchase Warrant, is entitled, at any time or from time to time from [●], 202[●] (the “Effective Date”),
being the date that is one hundred and eighty (180) days after the date of the commencement of the sales of the Company’s ordinary
shares, US$0.0001 par value per share (the “Ordinary Shares”), and at or before 5:00 p.m., Eastern time, on [●],
202[●] (five (5) years from the date hereof) (the “Expiration Date”), but not thereafter, to subscribe for, purchase
and receive, in whole or in part, up to [●] Ordinary Shares (equal to six (6.0%) percent of the Ordinary Shares sold in the offering
including any exercise of the overallotment option), subject to adjustment as provided in Section 6 hereof. If the Expiration
Date is a day on which banking institutions are authorized by law to close in New York City, New York, then this Purchase Warrant may
be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration
Date, the Company agrees not to take any action that would terminate this purchase warrant (“Purchase Warrant”). This
Purchase Warrant is initially exercisable at $[●] per Ordinary Share (120% of the price of the Ordinary Shares sold in the Offering);
provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted
by this Purchase Warrant, including the exercise price per share and the number of Ordinary Shares to be received upon such exercise,
shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth
above or the adjusted exercise price as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms
not defined herein shall have the meaning ascribed to them in the Underwriting Agreement. 

 

2. Exercise.

 

2.1 Exercise Form. In order to exercise
this Purchase Warrant, the exercise form attached hereto as Exhibit A must be duly executed and completed and delivered
to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Ordinary Shares being purchased payable
in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check. If the subscription
rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration Date, this Purchase Warrant shall
become and be void without further force or effect, and all rights represented hereby shall cease and expire.

 

 

		1	A date that is five years after the Effective Date of this Warrant.

 

     

     

    

 

2.2 Cashless Exercise. If at any time
after the Effective Date and until the Expiration Date, there is no effective registration statement registering the Ordinary Shares subject
to this Purchase Warrant, or the prospectus contained therein is not available for the issuance of the Ordinary Shares to the Holder,
Holder may elect to receive the number of Ordinary Shares equal to the value of this Purchase Warrant (or the portion thereof being exercised),
by surrender of this Purchase Warrant to the Company, together with the exercise form attached hereto, in which event the Company shall
issue to Holder, Shares in accordance with the following formula: 

 

X = Y(A-B)

A

 

Where,

 

	X	=	X	=	The number of Ordinary Shares to be issued to Holder;
	Y	=	Y	=	The number of Ordinary Shares for which the Purchase Warrant is being exercised;
	A	=	A	=	The fair market value of one Ordinary Share; and
	B	=	B	=	The Exercise Price.

 

For purposes of this Section 2.2,
the “fair market value” of an Ordinary Share is defined as follows: for any date, the price determined by the first of the
following clauses that applies: (a) if the Ordinary Shares are then listed or quoted on a national securities exchange, the bid price
of the Ordinary Shares for the time in question (or the nearest preceding date) on the national securities exchange on which the Ordinary
Shares are then listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:02 p.m.
(New York City time)), (b) if the Ordinary Shares are traded on OTCQB or OTCQX, the volume weighted average sales price of the Ordinary
Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Ordinary Shares are not then listed or
quoted for trading on OTCQB or OTCQX and if prices for the Ordinary Shares are then reported in the “Pink Sheets” published
by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid
price per share of the Ordinary Shares so reported, or (d) in all other cases, the fair market value of an Ordinary Shares as determined
by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.

 

2.3 Legend. Each certificate for the
Ordinary Shares purchased under this Purchase Warrant shall bear a legend as follows unless such Ordinary Shares have been registered
under the Securities Act of 1933, as amended (the “Act”), or are exempt from registration under the Act:

 

“The Ordinary Shares represented by this
certificate have not been registered under the Securities Act of 1933, as amended (the “Act”), or applicable state law. Neither
the Ordinary Shares nor any interest therein may be offered for sale, sold, or otherwise transferred except pursuant to an effective registration
statement under the Act, or pursuant to an exemption from registration under the Act and applicable state law which, in the opinion of
counsel to the Company, is available.”

 

3. Transfer.

 

3.1 General Restrictions. The registered
Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder will not: (a) sell, transfer, assign, pledge
or hypothecate this Purchase Warrant for a period of one hundred eighty (180) days following the Effective Date to anyone other than:
(i) the Underwriter or a representative or a selected dealer participating in the Offering, or (ii) a bona fide officer or partner of
the Underwriter or of any such selected dealer, in each case in accordance with FINRA Conduct Rule 5110(g)(1), or (b) cause this Purchase
Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would
result in the effective economic disposition of this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule
5110(g)(2). On and after that date that is one hundred eighty (180) days after the Effective Date, transfers to others may be made subject
to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver to
the Company the assignment form attached hereto as Exhibit B duly executed and completed, together with this Purchase
Warrant and payment of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) Business Days transfer
this Purchase Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor
to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of Ordinary Shares purchasable hereunder
or such portion of such number as shall be contemplated by any such assignment.

 

    2

     

    

 

3.2 Restrictions Imposed by the Act. The
securities evidenced by this Purchase Warrant shall not be transferred unless and until: (i) the Company has received the opinion of counsel
for the Company that the securities may be transferred pursuant to an exemption from registration under the Act and applicable state securities
laws, the availability of which is established to the reasonable satisfaction of the Company, (ii) a registration statement or a post-effective
amendment to the Registration Statement relating to the offer and sale of such securities that has been declared effective by the U.S.
Securities and Exchange Commission (the “Commission”) and includes a current prospectus or (iii) a registration statement,
pursuant to which the Holder has exercised its registration rights pursuant to Sections 4.1 and 4.2 herein, relating to the offer and
sale of such securities has been filed and declared effective by the Commission and compliance with applicable state securities law has
been established.

 

4. Registration Rights.

 

4.1 “Piggy-Back” Registration.
Unless all of the Ordinary Shares underlying the Purchase Warrants (collectively, the “Registrable Securities”) are included
in an effective registration statement with a current prospectus, the Holder shall have the right, until the Expiration Date, to include
the remaining Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with
a transaction contemplated by Rule 145 promulgated under the Act or pursuant to Form S-8 or any equivalent form); provided, however, that
if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof
shall, in its reasonable discretion, impose a limitation on the number of Ordinary Shares of Registrable Securities which may be included
in the registration statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary
to facilitate public distribution, then the Company shall be obligated to include in such registration statement only such limited portion
of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit;
and further provided that no such piggy-back rights shall exist for so long as the Registrable Securities (which term shall include those
paid as consideration pursuant to the cashless exercise provisions of this Warrant) may be sold pursuant to Rule 144 of the Act without
restriction. Any exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable Securities
in proportion to the number of Registrable Securities sought to be included by such Holders; provided, however, that the Company shall
not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not
entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable
Securities. In the event of such a proposed registration, the Company shall furnish the then Holders of outstanding Registrable Securities
with not less than fifteen (15) days written notice prior to the proposed date of filing of such registration statement. Such notice to
the Holders shall continue to be given for each registration statement filed by the Company until such time as all of the Registrable
Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the “piggy-back” rights
provided for herein by giving written notice, within seven (7) days of the receipt of the Company’s notice of its intention to file
a registration statement. Except as otherwise provided in this Purchase Warrant, there shall be no limit on the number of times the Holder
may request registration under this Section 4.1.

 

4.2 Mandatory Registration. Solely
in the event there is not then a current registration statement concerning the resale of the Registrable Securities, the Company shall
prepare and file with the SEC on one occasion at its sole expense, upon the written notice of the Holder at any time commencing six (6)
months after the date that this Warrant becomes exercisable and on or before the fifth anniversary date of the Effective Date, a required
registration statement (the “Required Registration Statement”) concerning the resale of all of the Registrable Securities.
The Required Registration Statement shall be on Form F-3 if available for such a registration and if unavailable, the Company shall register
the resale of the Registrable Securities on Form S-1 or another appropriate form reasonably acceptable to the Holder and undertake to
register the resale of the Registrable Securities on Form F-3 as soon as such form is available, provided that the Company shall maintain
the effectiveness of all Registration Statements then in effect until such time as a Registration Statement on Form F-3 covering the resale
of all of the Registrable Securities has been declared effective by the SEC and the prospectus contained therein is available for use.
Within ten (10) days after receiving written notice from the Holder, the Company shall give notice to the other Holders of the Purchase
Warrants advising that the Company is proceeding with such registration statement and offering to include therein Purchase Warrants of
such other Holders. The Company shall not be obligated to any such other Holder unless such other Holder shall accept such offer by notice
in writing to the Company within five (5) days thereafter. The Company shall use its best efforts to have such Required Registration Statement,
and each other Registration Statement required to be filed pursuant to the terms of this Purchase Warrant, declared effective by the SEC
as soon as practicable. The Company shall pay the costs and expenses thereof, for one time only, which costs and expenses shall include
“Blue Sky” fees for counsel for the Underwriter and “Blue Sky” filing fees to qualify the Purchase Warrants in
those jurisdictions requested by the Holder.

 

    3

     

    

 

4.3 General Terms.

 

4.3.1 Expenses of Registration. The
Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 4 hereof, but the Holders
shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection
with the sale of the Registrable Securities.

 

4.3.2 Indemnification. The Company
shall indemnify, to the fullest extent permitted by applicable laws, the Holder(s) of the Registrable Securities to be sold pursuant to
any registration statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Act or
Section 20 (a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), against all loss, claim, damage, expense
or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending
against any claim whatsoever) to which any of them may become subject under the Act, the Exchange Act or otherwise, arising from such
registration statement but only to the same extent and with the same effect as the provisions pursuant to which the Company has agreed
to indemnify the Underwriter contained in Section 6 of the Underwriting Agreement.

 

4.3.3 Exercise of Purchase Warrants.
Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise their Purchase Warrants prior to
or after the initial filing of any registration statement or the effectiveness thereof.

 

4.3.4 Documents to be Delivered by Holder(s). Each
of the Holder(s) participating in any of the registration statement filed by the Company shall furnish to the Company a completed and
executed questionnaire provided by the Company requesting information customarily sought of selling security holders.

 

4.3.5 Damages. Should the registration
or the effectiveness thereof required by Section 4 hereof be delayed by the Company or the Company otherwise fails to
comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s), be entitled
to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions or the
continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other security.

 

5. New Purchase Warrants to be Issued.

 

5.1 Partial Exercise or Transfer. Subject
to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in whole or in part. In the event of the exercise
or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation, together with the duly executed exercise
or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised pursuant to Section 2.1 hereof, the
Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor to this Purchase Warrant in the
name of the Holder evidencing the right of the Holder to purchase the number of Ordinary Shares purchasable hereunder as to which this
Purchase Warrant has not been exercised or assigned.

 

5.2 Lost Certificate. Upon receipt by the
Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant and of reasonably satisfactory
indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant of like tenor and date. Any such
new Purchase Warrant executed and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual
obligation on the part of the Company.

 

    4

     

    

 

6. Adjustments.

 

6.1 Adjustments to Exercise Price and Number
of Ordinary Shares. The Exercise Price and the number of Ordinary Shares underlying this Purchase Warrant shall be subject to adjustment
from time to time as hereinafter set forth:

 

6.1.1 Share Dividends; Split Ups. If, after
the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding Ordinary Shares are increased by a share
dividend payable in Ordinary Shares or by a split up of the Ordinary Shares or other similar events, then, on the effective day thereof,
the number of Ordinary Shares purchasable hereunder shall be increased in proportion to such increase in outstanding Ordinary Shares,
and the Exercise Price shall be proportionately decreased.

 

6.1.2 Subsequent Equity Sales. If the Company
or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall sell, enter into an agreement to sell,
or grant any option to purchase, or sell, enter into an agreement to sell, or grant any right to reprice, or otherwise dispose of or issue
(or announce any offer, sale, grant or any option to purchase or other disposition) any Ordinary Shares or Ordinary Share Equivalents,
at an effective price per share less than the Exercise Price then in effect (such lower price, the “Base Share Price”
and such issuances collectively, a “Dilutive Issuance”) (it being understood and agreed that if the holder of the Ordinary
Shares or Ordinary Share Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions,
floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection
with such issuance, be entitled to receive Ordinary Shares at an effective price per share that is less than the Exercise Price, such
issuance shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance at such effective price),
then simultaneously with the consummation (or, if earlier, the announcement) of each Dilutive Issuance the Exercise Price shall be reduced
and only reduced to equal the Base Share Price provided that the Base Share Price shall not be less than $[●] (subject to adjustment
for reverse and forward share splits, recapitalizations and similar transactions following the Initial Issuance Date). Notwithstanding
the foregoing, no adjustments shall be made, paid or issued under this Section 3(b) in respect of an Exempt Issuance. The Company shall
notify the Holder, in writing, no later than the Trading Day following the issuance or deemed issuance of any Ordinary Shares or Ordinary
Share Equivalents subject to this Section 3(b), indicating therein the applicable issuance price, or applicable reset price, exchange
price, conversion price and other pricing terms (such notice, the “Dilutive Issuance Notice”). For purposes of clarification,
whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 3(b), upon the occurrence of any Dilutive Issuance,
the Holder is entitled to receive a number of Warrant Shares based upon the Base Share Price regardless of whether the Holder accurately
refers to the Base Share Price in the Notice of Exercise. If the Company enters into a Variable Rate Transaction, the Company shall be
deemed to have issued Ordinary Shares or Ordinary Share Equivalents at the lowest possible price, conversion price or exercise price at
which such securities may be issued, converted or exercised. An “Exempt Issuance” means the issuance of (a) Ordinary
Shares or options to employees, officers, directors or consultants of the Company pursuant to any share or option plan duly adopted for
such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee
directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion
of the Ordinary Shares to be issued hereunder and/or other securities exercisable or exchangeable for or convertible into Ordinary Shares
issued and outstanding on the date of this Warrant, provided that such securities have not been amended since the date of this Warrant
to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other
than in connection with share dividends, share splits or combinations) or to extend the term of such securities, (c) securities in connection
with an underwritten public offering, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority
of the disinterested directors of the Company, provided that any such issuance shall only be to a person or entity ("Person")
(or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a
business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment
of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital
or to an entity whose primary business is investing in securities.

 

6.1.3 Aggregation of Ordinary Shares. If,
after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding Ordinary Shares is decreased by a
consolidation, combination or reclassification of the Ordinary Shares or other similar events, then, on the effective date thereof, the
number of Ordinary Shares hereunder shall be decreased in proportion to such decrease in outstanding shares, and the Exercise Price shall
be proportionately increased.

 

    5

     

    

 

6.1.4 Replacement of Ordinary Shares upon Reorganization,
etc. In case of any reclassification or reorganization of the outstanding Ordinary Shares other than a change covered by Section 6.1.1,
6.1.2 or Section 6.1.3 hereof or that solely affects the par value of such Ordinary Shares, or in the case of any share reconstruction
or amalgamation or consolidation of the Company with or into another corporation (other than a consolidation or share reconstruction or
amalgamation in which the Company is the continuing corporation and that does not result in any reclassification or reorganization of
the outstanding Ordinary Shares), or in the case of any sale or conveyance to another corporation or entity of the property of the Company
as an entirety or substantially as an entirety in connection with which the Company is dissolved, the Holder of this Purchase Warrant
shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise
hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event, the kind and amount of Ordinary Shares
or other securities or property (including cash) receivable upon such reclassification, reorganization, share reconstruction or amalgamation,
or consolidation, or upon a dissolution following any such sale or transfer, by a Holder of the number of Ordinary Shares of the Company
obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results in a change
in Ordinary Shares covered by Section 6.1.1, 6.1.2 or Section 6.1.3, then such adjustment shall be made pursuant to Section 6.1.1, Section
6.1.2, 6.1.3 and this Section 6.1.34 The provisions of this Section 6.1.4 shall similarly apply to successive reclassifications, reorganizations,
share reconstructions or amalgamations, or consolidations, sales or other transfers.

 

6.1.5 Fundamental Transaction. If, at any
time while this Purchase Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related
transactions, (iii) any direct or indirect purchase offer, tender offer or exchange offer (whether by the Company or another Person) is
completed pursuant to which holders of the Ordinary Shares are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares, (iv) the Company, directly or
indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares
or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spinoff or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Ordinary Shares (not
including any Ordinary Shares held by the other Person or other Persons making or party to, or associated or affiliated with, the other
Persons making or party to such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Purchase Warrant, the Holder shall have the right to receive, for each Purchase Warrant Share
that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number Ordinary
Shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional or alternative
consideration (the “Alternative Consideration”) receivable as a result of such Fundamental Transaction by a holder of the
number of Ordinary Shares for which this Purchase Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternative Consideration
based on the amount of Alternative Consideration issuable in respect of one Ordinary Share in such Fundamental Transaction, and the Company
shall apportion the Exercise Price among the Alternative Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternative Consideration. If holders of the Ordinary Shares are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternative Consideration it receives
upon any exercise of this Purchase Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations
of the Company under this Purchase Warrant, and to deliver to the Holder in exchange for this Purchase Warrant a security of the Successor
Entity evidenced by a written instrument substantially similar in form and substance to this Purchase Warrant which is exercisable for
a corresponding number of shares of capital stock or other equity interests of such Successor Entity (or its parent entity) equivalent
to the Ordinary Shares acquirable and receivable upon exercise of this Purchase Warrant prior to such Fundamental Transaction, and with
an exercise price which applies the Exercise Price hereunder to such shares of capital stock or other equity interests (but taking into
account the relative value of the Ordinary Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock
or other equity interests, such number of shares of capital stock or other equity interests and such exercise price being for the purpose
of protecting the economic value of this Purchase Warrant immediately prior to the consummation of such Fundamental Transaction). Upon
the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after
the date of such Fundamental Transaction, the provisions of this Purchase Warrant and the other Transaction Documents referring to the
“Company” shall refer instead to the Successor Entity), and may exercise every right and power of, the Company and shall assume
all of the obligations of the Company, under this Purchase Warrant and the other Transaction Documents with the same effect as if such
Successor Entity had been named as the Company herein.

 

    6

     

    

 

6.1.6 Changes in Form of Purchase Warrant.
This form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1, and Purchase Warrants issued after
such change may state the same Exercise Price and the same number of Ordinary Shares as are stated in the Purchase Warrants initially
issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase Warrants reflecting a required or permissive
change shall not be deemed to waive any rights to an adjustment occurring after the date hereof or the computation thereof.

 

6.2 Substitute Purchase Warrant. In case
of any consolidation of the Company with, or share reconstruction or amalgamation of the Company with or into, another corporation (other
than a consolidation or share reconstruction or amalgamation which does not result in any reclassification or change of the outstanding
Ordinary Shares), the corporation formed by such consolidation or share reconstruction or amalgamation shall execute and deliver to the
Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding or to be outstanding shall
have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise of such Purchase Warrant, the
kind and amount of Ordinary Shares and other securities and property receivable upon such consolidation or share reconstruction or amalgamation,
by a holder of the number of Ordinary Shares of the Company for which such Purchase Warrant might have been exercised immediately prior
to such consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental Purchase Warrant shall provide for adjustments
which shall be identical to the adjustments provided for in this Section 6. The above provision of this Section 6 shall similarly apply
to successive consolidations or share reconstructions or amalgamations.

 

6.3 Elimination of Fractional Interests.
The Company shall not be required to issue certificates representing fractions of an Ordinary Share upon the exercise of the Purchase
Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that
all fractional interests shall be eliminated by rounding any fraction up to the nearest whole number of Ordinary Shares or other securities,
properties or rights.

 

7. Reservation and Listing. The Company
shall at all times reserve and keep available out of its authorized but unissued Ordinary Shares, solely for the purpose of issuance upon
exercise of this Purchase Warrant, such number of Ordinary Shares or other securities, properties or rights as shall be issuable upon
the exercise thereof. The Company covenants and agrees that, upon exercise of this Purchase Warrant and payment of the Exercise Price
therefor, in accordance with the terms hereby, all Ordinary Shares and other securities issuable upon such exercise shall be duly and
validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder. As long as this Purchase Warrant
shall be outstanding, the Company shall use its commercially reasonable efforts to cause all Ordinary Shares issuable upon exercise of
this Purchase Warrant to be listed (subject to official notice of issuance) on all national securities exchanges (or, if applicable, on
the OTCQB Market or any successor quotation system) on which the Ordinary Shares issued to the public in the Offering may then be listed
and/or quoted (if at all).

 

8. Certain Notice Requirements.

 

8.1 Holder’s Right to Receive Notice.
Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to receive notice as a shareholder for
the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the Company. If, however, at any
time prior to the expiration of the Purchase Warrants and their exercise, any of the events described in Section 8.2 shall occur, then,
in one or more of said events, the Company shall give written notice of such event at least fifteen days prior to the date fixed as a
record date or the date of closing the transfer books (the “Notice Date”) for the determination of the shareholders entitled
to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such proposed dissolution,
liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing of the transfer books, as the case
may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of each notice given to the other shareholders
of the Company at the same time and in the same manner that such notice is given to the shareholders.

 

    7

     

    

 

8.2 Events Requiring Notice. The Company
shall be required to give the notice described in this Section 8 upon one or more of the following events: (i) if the Company shall
take a record of the holders of its Ordinary Shares for the purpose of entitling them to receive a dividend or distribution payable otherwise
than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment
of such dividend or distribution on the books of the Company, (ii) the Company shall offer to all the holders of its Ordinary Shares any
additional shares of the Company or securities convertible into or exchangeable for shares of the Company, or any option, right or warrant
to subscribe therefor, or (iii) a dissolution, liquidation or winding up of the Company (other than in connection with a consolidation
or share reconstruction or amalgamation) or a sale of all or substantially all of its property, assets and business shall be proposed. 

 

8.3 Notice of Change in Exercise Price.
The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section 6 hereof, send
notice to the Holders of such event and change (“Price Notice”). The Price Notice shall describe the event causing the change
and the method of calculating same and shall be certified as being true and accurate by the Company’s Chief Financial Officer.

 

8.4 Transmittal of Notices. All notices,
requests, consents and other communications under this Purchase Warrant shall be in writing and shall be deemed to have been duly made
if made in accordance with the notice provisions of the Underwriting Agreement to the addresses and contact information for the Holder
appearing on the books and records of the Company.

 

If to the Holder, then to:

 

Univest Securities, LLC

75 Rockefeller Plaza, Suite 1838

New York, New York 10019

Attn: Mr. Edric Guo, Chief Executive Officer

Email: yguo@univest.us

 

with a copy (which shall not constitute notice)
to:

 

Carmel, Milazzo & Feil LLP

55 West 39th Street

18th Floor

New York, NY 10018

Attn: Ross Carmel, Esq.

Email: rcarmel@cmfllp.com

 

 If to the Company:

 

Li Bang International Corporation Inc.

No. 190 Xizhang Road, Gushan Town

Jiangyin City, Jiangsu Province

Attn: Mr. Huang Feng, Chief Executive Officer
and Chairman of Board

Email: huangfeng@libangco.com

 

With a copy (which shall not constitute
notice) to:

 

Ortoli Rosenstadt LLP

366 Madison Avenue, 3rd Floor

New York, NY 10022-5616

Attn: Mengyi “Jason” Ye, Esq.

Emails: jye@orllp.legal

 

    8

     

    

 

9. Miscellaneous.

 

9.1 Amendments. The Company and the
Underwriter may from time to time supplement or amend this Purchase Warrant without the approval of any of the Holders in order to cure
any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with any other provisions
herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company and the Underwriter may deem
necessary or desirable and that the Company and the Underwriter deem shall not adversely affect the interest of the Holders. All other
modifications or amendments shall require the written consent of and be signed by the party against whom enforcement of the modification
or amendment is sought.

 

9.2 Headings. The headings contained
herein are for the sole purpose of convenience of reference and shall not in any way limit or affect the meaning or interpretation of
any of the terms or provisions of this Purchase Warrant.

 

9.3 Entire Agreement. This Purchase
Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this Purchase Warrant) constitutes
the entire agreement of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings
of the parties, oral and written, with respect to the subject matter hereof.

 

9.4 Binding Effect. This Purchase
Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted assignees, respective
successors, legal representative and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy
or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein contained.

 

9.5 Governing Law; Submission to Jurisdiction;
Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced in accordance with the laws of the State of New
York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against
it arising out of, or relating in any way to this Purchase Warrant shall be brought and enforced in the New York Supreme Court, County
of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction,
which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent
an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof.
Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding, or claim. The
Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies)
all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the
preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates)
and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any
legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

 

9.6 Waiver, etc. The failure of the
Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed or construed to be a waiver
of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof or the right of the Company
or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver of any breach, non-compliance or non-fulfillment
of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument executed by the party or
parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment
shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

 

    9

     

    

 

9.7 Exchange Agreement. As a condition
of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any time prior to the complete exercise
of this Purchase Warrant by Holder, if the Company and the Underwriter enter into an agreement (“Exchange Agreement”) pursuant
to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash or a combination of both, then Holder
shall agree to such exchange and become a party to the Exchange Agreement.

 

9.8 Execution in Counterparts. This
Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which
shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement and shall become effective
when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Such counterparts
may be delivered by facsimile transmission or other electronic transmissions.

 

9.9 Holder Not Deemed a Shareholder.
Except as otherwise specifically provided herein, the Holder, solely in its capacity as a holder of this Purchase Warrant, shall not be
entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained
in this Purchase Warrant be construed to confer upon the Holder, solely in its capacity as the Holder of this Purchase Warrant, any of
the rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization,
issue of share, reclassification of share, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends
or subscription rights, or otherwise, prior to the issuance to the Holder of the Ordinary Shares which it is then entitled to receive
upon the due exercise of this Purchase Warrant. In addition, nothing contained in this Purchase Warrant shall be construed as imposing
any liabilities on the Holder to purchase any securities (upon exercise of this Purchase Warrant or otherwise) or as a shareholder of
the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

9.10 Restrictions. The Holder acknowledges
that the Shares acquired upon the exercise of this Purchase Warrant, if not registered, and the Holder does not utilize cashless exercise,
will have restrictions upon resale imposed by state and federal securities laws.

 

9.11 Severability. Wherever possible,
each provision of this Purchase Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if
any provision of this Purchase Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to
the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this
Purchase Warrant.

 

[Signature Page to Follow]

 

    10

     

    

 

IN WITNESS WHEREOF, the Company has caused
this Purchase Warrant to be signed by its duly authorized officer as of the [●] day of [●], 202[●].

 

	 	LI BANG INTERNATIONAL CORPORATION INC.
	 	 	 
	 	By:	        
	 	Name:	 
	 	Title:	Director

 

[SIGNATURE PAGE TO UNDERWRITERS WARRANT AGREEMENT]

 

    11

     

    

 

Form to be used to exercise Purchase Warrant:

 

Date: __________, 20___

 

The undersigned hereby elects irrevocably to exercise
the Purchase Warrant for ______ Ordinary Shares of Li Bang International Corporation Inc. (the “Company”) and hereby
makes payment of $____ (at the rate of $____ per Ordinary Share) in payment of the Exercise Price pursuant thereto. Please issue the Ordinary
Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase
Warrant representing the number of Ordinary Shares for which this Purchase Warrant has not been exercised.

 

or 

 

The undersigned hereby elects irrevocably to convert
its right to purchase ___ Ordinary Shares under the Purchase Warrant for ______Ordinary Shares, as determined in accordance with the following
formula:

 

	 	 X	 =	Y(A-B)	 
	 	A	 
	Where,	X	=	The number of Ordinary Shares to be issued to Holder;
	 	Y	=	The number of Ordinary Shares for which the Purchase Warrant is being exercised;
	 	A	=	The fair market value of one Ordinary Share which is equal to $_____; and
	 	B	=	The Exercise Price which is equal to $______ per Ordinary Share.

The undersigned agrees and acknowledges that the
calculation set forth above is subject to confirmation by the Company and any disagreement with respect to the calculation shall be resolved
by the Company in its sole discretion.

 

Please issue the Ordinary Shares as to which this
Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing
the number of Ordinary Shares for which this Purchase Warrant has not been converted.

 

Signature: _____________________________________________

 

Signature Guaranteed

 

 INSTRUCTIONS FOR REGISTRATION OF SECURITIES

 

 Name:_______________________________________________________

 

(Print in Block Letters)

 

Address: _____________________________________________________

 

 NOTICE: The signature to this form must
correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national
securities exchange.

 

    12

     

    

 

 

Form to be used to assign Purchase Warrant:
ASSIGNMENT

 

(To be executed by the registered Holder to effect
a transfer of the within Purchase Warrant):

 

FOR VALUE RECEIVED, _______________________________
does hereby sell, assign and transfer unto the right to purchase __________  Ordinary Shares , Li Bang International
Corporation Inc., a Cayman Islands exempted company (the “Company”), evidenced by the Purchase Warrant and does hereby
authorize the Company to transfer such right on the books of the Company.

 

Dated:______, 20____ 

 

Signature: _______________________________________

 

Signature Guaranteed

 

NOTICE: The signature to this form must correspond
with the name as written upon the face of the within Purchase Warrant without alteration or enlargement or any change whatsoever, and
must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national
securities exchange.

 

 

13Exhibit 10.4

 

Li Bang International Corporation Inc.

 

No. 190 Xizhang Road, Gushan Town

Jiangyin City, Jiangsu Province

People’s Republic of China 214413

 

May 14, 2022

 

Re: Director Offer Letter – Funa Li

 

Dear Ms. Li:

 

Li Bang International Corporation
Inc., a Cayman Islands limited liability company (the “Company” or “we”), is pleased to offer you a position as
a Director of the Company. We believe your background and experience will be a significant asset to the Company and we look forward
to your participation as a Director in the Company. Should you choose to accept this position as a Director, this letter agreement (the
“Agreement”) shall constitute an agreement between you and the Company and contains all the terms and conditions relating
to the services you agree to provide to the Company.

 

1. Term.  This
Agreement is effective as of the date of this Agreement. Your term as a Director shall continue subject to the provisions in Section 9
below or until your successor is duly elected and qualified.  The position shall be up for re-appointment every year by the
board of the Directors of the Company (the “Board”) and upon re-appointment, the terms and provisions of this Agreement shall
remain in full force and effect.

 

2. Services.  You
shall render customary services as a Director (hereinafter, your “Duties”). During the term of this Agreement, you may attend
and participate at each meeting regarding the business and operation issues of the Company as regularly or specially called, via teleconference,
video conference or in person. You shall consult with the members of the Board and committee (if any) regularly and as necessary via telephone,
electronic mail or other forms of correspondence.

 

3. Services
for Others.  You shall be free to represent or perform services for other persons during the term of this Agreement.  

 

4. Compensation.  As
compensation for your services to the Company, you will receive upon execution of this Agreement a compensation of $30,000 for each calendar
year of service under this Agreement on a pro-rated basis, payable on a monthly basis.

 

You shall be reimbursed for
reasonable expenses incurred by you in connection with the performance of your Duties (including travel expenses for in-person meetings).

 

5. D&O
Insurance Policy. During the term under this Agreement, the Company shall include you as an insured under its officers and
directors insurance policy, if available.

 

6. No
Assignment.  Because of the personal nature of the services to be rendered by you, this Agreement may not be assigned
by you without the prior written consent of the Company.

 

     

     

    

 

7. Confidential
Information; Non-Disclosure.  In consideration of your access to certain Confidential Information (as defined below)
of the Company, in connection with your business relationship with the Company, you hereby represent and agree as follows:

 

a. Definition.  For
purposes of this Agreement the term “Confidential Information” means: (i) any information which the Company possesses that
has been created, discovered or developed by or for the Company, and which has or could have commercial value or utility in the business
in which the Company is engaged; (ii) any information which is related to the business of the Company and is generally not known by non-Company
personnel; and (iii) Confidential Information includes, without limitation, trade secrets and any information concerning products, processes,
formulas, designs, inventions (whether or not patentable or registrable under copyright or similar laws, and whether or not reduced to
practice), discoveries, concepts, ideas, improvements, techniques, methods, research, development and test results, specifications, data,
know-how, software, formats, marketing plans, and analyses, business plans and analyses, strategies, forecasts, customer and supplier
identities, characteristics and agreements.

 

b. Exclusions.  Notwithstanding
the foregoing, the term Confidential Information shall not include: (i) any information which becomes generally available or is readily
available to the public other than as a result of a breach of the confidentiality portions of this Agreement, or any other agreement requiring
confidentiality between the Company and you; (ii) information received from a third party in rightful possession of such information
who is not restricted from disclosing such information; (iii) information known by you prior to receipt of such information from the Company,
which prior knowledge can be documented and (iv) information you are required to disclose pursuant to any applicable law, regulation,
judicial or administrative order or decree, or request by other regulatory organization having authority pursuant to the law; provided,
however, that you shall first have given prior written notice to the Company and made a reasonable effort to obtain a protective order
requiring that the Confidential Information not be disclosed.

 

c. Documents. You
agree that, without the express written consent of the Company, you will not remove from the Company’s premises, any notes, formulas,
programs, data, records, machines or any other documents or items which in any manner contain or constitute Confidential Information,
nor will you make reproductions or copies of same.  You shall promptly return any such documents or items, along with any reproductions
or copies to the Company upon the Company’s demand, upon termination of this Agreement, or upon your termination or Resignation
(as defined in Section 9 herein).

 

d. Confidentiality.  You
agree that you will hold in trust and confidence all Confidential Information and will not disclose to others, directly or indirectly,
any Confidential Information or anything relating to such information without the prior written consent of the Company, except as may
be necessary in the course of your business relationship with the Company.  You further agree that you will not use any Confidential
Information without the prior written consent of the Company, except as may be necessary in the course of your business relationship with
the Company, and that the provisions of this paragraph (d) shall survive termination of this Agreement. Notwithstanding the foregoing,
you may disclose Confidential Information to your legal counsel and accounting advisors who have a need to know such information for accounting
or tax purposes and who agree to be bound by the provisions of this paragraph (d).

 

e. Ownership.  You
agree that the Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights,
trademark rights, and all other intellectual and industrial property rights of any sort throughout the world) relating to any and all
inventions (whether or not patentable), works of authorship, mask works, designations, designs, know-how, ideas and information made or
conceived or reduced to practice, in whole or in part, by you during the term of this Agreement and that arise out of your Duties (collectively,
“Inventions”) and you will promptly disclose and provide all Inventions to the Company. You agree to assist the Company,
at its expense, to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights
assigned.

 

8.  Non-Solicitation.  
During the term of your appointment, you shall not solicit for employment any employee of the Company with whom you have had contact due
to your appointment.

 

9.  Termination
and Resignation.  Your services as a Director may be terminated for any or no reason by the determination of the Board.
You may also terminate your services as a Director for any or no reason by delivering your written notice of resignation to the Company
(“Resignation”), and such Resignation shall be effective upon the time specified therein or, if no time is specified, upon
receipt of the notice of resignation by the Company. Upon the effective date of the termination or Resignation, your right to compensation
hereunder will terminate subject to the Company’s obligations to pay you any compensation that you have already earned and to reimburse
you for approved expenses already incurred in connection with your performance of your Duties as of the effective date of such termination
or Resignation.

 

    2

     

    

 

10. Governing
Law; Arbitration. All questions with respect to the construction and/or enforcement of this Agreement,
and the rights and obligations of the parties hereunder, shall be determined in accordance with the law of the State of New York. All
disputes with respect to this Agreement, including the existence, validity, interpretation, performance, breach or termination thereof
or any dispute regarding non-contractual obligations arising out of or relating to it shall be referred to and finally resolved by arbitration
administered by the American Arbitration Association at its New York office in force when the Notice of Arbitration is submitted. The
law of this arbitration clause shall be New York law. The seat of arbitration shall be in New York. The number of arbitrators shall be
one. The arbitration proceedings shall be conducted in English.

 

11. Entire
Agreement; Amendment; Waiver; Counterparts.  This Agreement expresses the entire understanding with respect to the subject
matter hereof and supersedes and terminates any prior oral or written agreements with respect to the subject matter hereof.  Any
term of this Agreement may be amended and observance of any term of this Agreement may be waived only with the written consent of the
parties hereto.  Waiver of any term or condition of this Agreement by any party shall not be construed as a waiver of any subsequent
breach or failure of the same term or condition or waiver of any other term or condition of this Agreement.  The failure of
any party at any time to require performance by any other party of any provision of this Agreement shall not affect the right of any such
party to require future performance of such provision or any other provision of this Agreement.  This Agreement may be executed
in separate counterparts each of which will be an original and all of which taken together will constitute one and the same agreement,
and may be executed using facsimiles of signatures, and a facsimile of a signature shall be deemed to be the same, and equally enforceable,
as an original of such signature.

 

12. Indemnification.  The
Company shall, to the maximum extent provided under applicable law, indemnify and hold you harmless from and against any expenses,
including reasonable attorney’s fees, judgments, fines, settlements and other legally permissible amounts
(“Losses”), incurred in connection with any proceeding arising out of, or related to, your performance of your Duties,
other than any such Losses incurred as a result of your gross negligence or willful misconduct.  The Company shall advance
to you any expenses, including reasonable attorneys’ fees and costs of settlement, incurred in defending any such proceeding
to the maximum extent permitted by applicable law.  Such costs and expenses incurred by you in defense of any such
proceeding shall be paid by the Company in advance of the final disposition of such proceeding promptly upon receipt by the Company
of (a) written request for payment; (b) appropriate documentation evidencing the incurrence, amount and nature of the costs and
expenses for which payment is being sought; and (c) an undertaking adequate under applicable law made by or on your behalf to repay
the amounts so advanced if it shall ultimately be determined pursuant to any non-appealable judgment or settlement that you are not
entitled to be indemnified by the Company. 

 

13. Acknowledgement.  
You accept this Agreement subject to all the terms and provisions of this Agreement. You agree to accept as binding, conclusive, and
final all decisions or interpretations of the Board of Directors of the Company of any questions arising under this Agreement.

 

    3

     

    

 

The Agreement has been executed and delivered by
the undersigned and is made effective as of the date set first set forth above.

 

	 	Sincerely,
	 	 	 
	 	Li Bang International Corporation Inc.
	 	 	 
	 	By: 	/s/ Feng Huang
	 	 	Feng Huang
	 	 	Chief Executive Officer and Chairman

 

	AGREED AND ACCEPTED:
	 	 
	/s/ Funa
Li	 

Funa Li

Address:

 

Phone Number:

Email: 

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]